CA2650718A1 - Procedes de traitement de la dystrophie musculaire associee a une deficience en dysferline - Google Patents

Procedes de traitement de la dystrophie musculaire associee a une deficience en dysferline Download PDF

Info

Publication number
CA2650718A1
CA2650718A1 CA002650718A CA2650718A CA2650718A1 CA 2650718 A1 CA2650718 A1 CA 2650718A1 CA 002650718 A CA002650718 A CA 002650718A CA 2650718 A CA2650718 A CA 2650718A CA 2650718 A1 CA2650718 A1 CA 2650718A1
Authority
CA
Canada
Prior art keywords
antibody
mammal
dysferlin
antibodies
complement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002650718A
Other languages
English (en)
Inventor
Simone Spuler
Russell Rother
Katrin Wenzel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Publication of CA2650718A1 publication Critical patent/CA2650718A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne l'utilisation de traitements capables d'inhiber le complément tels qu'un anticorps anti-C5 afin de traiter une dystrophie musculaire associée à une déficience en dysferline.
CA002650718A 2006-05-01 2006-05-01 Procedes de traitement de la dystrophie musculaire associee a une deficience en dysferline Abandoned CA2650718A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2006/016980 WO2007130031A1 (fr) 2006-05-01 2006-05-01 Procedes de traitement de la dystrophie musculaire associee a une deficience en dysferline

Publications (1)

Publication Number Publication Date
CA2650718A1 true CA2650718A1 (fr) 2007-11-15

Family

ID=37866247

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002650718A Abandoned CA2650718A1 (fr) 2006-05-01 2006-05-01 Procedes de traitement de la dystrophie musculaire associee a une deficience en dysferline

Country Status (4)

Country Link
EP (1) EP2013235A1 (fr)
AU (1) AU2006343402A1 (fr)
CA (1) CA2650718A1 (fr)
WO (1) WO2007130031A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090220508A1 (en) 2006-03-15 2009-09-03 Alexion Pharmaceuticals, Inc. Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement
WO2008048689A2 (fr) * 2006-10-20 2008-04-24 Alexion Pharmaceuticals, Inc. Méthodes de traitement d'une dystrophie musculaire associée à une carence en dysferline
ES2940466T3 (es) * 2008-11-10 2023-05-08 Alexion Pharma Inc Métodos y composiciones para tratar trastornos asociados al complemento

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis

Also Published As

Publication number Publication date
EP2013235A1 (fr) 2009-01-14
AU2006343402A1 (en) 2007-11-15
WO2007130031A1 (fr) 2007-11-15

Similar Documents

Publication Publication Date Title
US10703809B1 (en) Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
IL259079B2 (en) Anti-complement factor c1q fab fragments and their uses
BRPI0619357B1 (pt) Anticorpos monoclonais, composição farmacêutica, vacina, uso dos mesmos para tratamento ou prevenção de doença de alzheimer, métodos in vitro para diagnosticar e para identificar compostos apropriados para imunização de doença de alzheimer e kits
EP2576617A2 (fr) ANTICORPS MONOCLONAUX CIBLANT DES OLIGOMÈRES Aß
US20090041764A1 (en) Methods for the treatment of muscular dystrophy associated with dysferlin-deficiency
CA2650718A1 (fr) Procedes de traitement de la dystrophie musculaire associee a une deficience en dysferline
BR112016027671B1 (pt) Uso de um anticorpo
JP2019210290A (ja) 代謝性疾患を処置する方法
CN117561078A (zh) 用于评价发展急性covid-19和急性后covid-19的风险的生物标志物

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20100503